Monday, February 26, 2024
Saghmos Therapeutics is developing ST-62516 to reduce the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) after contrast procedures such as percutaneous coronary intervention (PCI). Saghmos’ IND for ST-62516 was cleared by the FDA in July 2023. The company anticipates that its Phase 3 study can be initiated in 2024. Acute Kidney Injury and cardiorenal complications are an area of high unmet need. Patients with pre-existing Chronic Kidney Disease (CKD) and comorbidities such as diabetes and heart disease are at high risk of complications, including heart failure and progression of kidney disease, leading to prolonged hospitalization and need for dialysis. There are no approved pharmacologic agents to prevent or treat the problem. Prevention and treatment of AKI and cardiorenal complications has multi-billion dollar revenue potential.
CEO/Top Company Official
Anna Kazanchyan, M.D., Founder, CEO
Lead Product in Development
Development Phase of Primary Product
Number Of Unlicensed Products